Published in Genes Chromosomes Cancer on December 01, 2007
The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem (2008) 1.67
Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem (2009) 1.28
Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19
Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One (2009) 1.18
WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol (2010) 1.16
Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol (2012) 1.12
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood (2011) 1.01
Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Hum Mol Genet (2010) 0.98
WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta (2014) 0.98
A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development. Eur J Hum Genet (2011) 0.97
Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. Genes Cancer (2011) 0.96
Common fragile site tumor suppressor genes and corresponding mouse models of cancer. J Biomed Biotechnol (2010) 0.93
DSDs: genetics, underlying pathologies and psychosexual differentiation. Nat Rev Endocrinol (2014) 0.91
Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol (2013) 0.91
Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep (2015) 0.85
The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism. Exp Biol Med (Maywood) (2014) 0.85
WWOX: a fragile tumor suppressor. Exp Biol Med (Maywood) (2014) 0.84
Translational genetics for diagnosis of human disorders of sex development. Annu Rev Genomics Hum Genet (2013) 0.83
Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells. J Biol Chem (2015) 0.82
WWOX, the chromosomal fragile site FRA16D spanning gene: its role in metabolism and contribution to cancer. Exp Biol Med (Maywood) (2015) 0.79
Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster. PLoS One (2015) 0.78
WWOX, large common fragile site genes, and cancer. Exp Biol Med (Maywood) (2015) 0.78
Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2014) 0.77
Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma. Exp Biol Med (Maywood) (2014) 0.75
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. Cell Death Dis (2017) 0.75
Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett (2017) 0.75
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Expression profiling in primates reveals a rapid evolution of human transcription factors. Nature (2006) 4.26
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mamm Genome (1997) 2.47
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene (2005) 1.90
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene (2004) 1.47
Efficiency assessment of the gene trap approach. Dev Dyn (1998) 1.45
Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat (2005) 1.33
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res (2003) 1.32
The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics (2000) 1.31
WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res (2003) 1.28
An opposing view on WWOX protein function as a tumor suppressor. Cancer Res (2003) 1.27
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
WWOX protein expression in normal human tissues. J Mol Histol (2006) 1.22
Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer (2004) 1.22
The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer (2002) 1.22
Role for c-Abl and p73 in the radiation response of male germ cells. Oncogene (2001) 0.99
Unique patterns of gene expression changes in liver after treatment of mice for 2 weeks with different known carcinogens and non-carcinogens. Carcinogenesis (2004) 0.94
Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol (2004) 0.93
Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep (2006) 5.19
Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science (2006) 4.54
p53 is regulated by the lysine demethylase LSD1. Nature (2007) 4.53
A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev (2008) 3.16
Proteome-wide analysis in Saccharomyces cerevisiae identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylated at either lysine 4 or lysine 36. J Biol Chem (2006) 3.14
Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics (2003) 3.06
REST maintains self-renewal and pluripotency of embryonic stem cells. Nature (2008) 3.06
The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol Cell (2007) 2.94
The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem (2001) 2.63
Protein arginine methyltransferases and cancer. Nat Rev Cancer (2012) 2.56
Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A (2003) 2.50
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) 2.50
Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem (2003) 2.12
PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays. EMBO Rep (2002) 2.11
Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
Overdispersed logistic regression for SAGE: modelling multiple groups and covariates. BMC Bioinformatics (2004) 2.01
Small molecule regulators of protein arginine methyltransferases. J Biol Chem (2004) 1.99
Histone arginine methylation. FEBS Lett (2010) 1.95
Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell (2003) 1.87
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res (2004) 1.83
TDRD3 is an effector molecule for arginine-methylated histone marks. Mol Cell (2010) 1.80
Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat Struct Mol Biol (2012) 1.77
Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics (2005) 1.75
Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression. EMBO J (2004) 1.74
Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions. Cell Cycle (2011) 1.74
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol (2013) 1.72
Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res (2004) 1.71
Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A (2006) 1.69
Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem (2007) 1.68
PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem (2005) 1.67
Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks. PLoS One (2009) 1.66
Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst (2012) 1.58
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics (2013) 1.53
A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics. Nucleic Acids Res (2009) 1.49
Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res (2003) 1.48
WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene (2004) 1.47
Normalization of nomenclature for peptide motifs as ligands of modular protein domains. FEBS Lett (2002) 1.46
Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res (2007) 1.45
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
A protein-domain microarray identifies novel protein-protein interactions. Biochem J (2002) 1.42
Complexity of VEGF responses in skin carcinogenesis revealed through ex vivo assays based on a VEGF-A null mouse keratinocyte cell line. J Invest Dermatol (2008) 1.42
The radiation-induced nackt (nkt) allele is a loss-of-function mutation of the mouse cathepsin L gene. J Immunol (2006) 1.40
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol (2011) 1.40
Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3). Biochem J (2005) 1.40
Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol (2010) 1.37
Regulation of protein arginine methyltransferase 8 (PRMT8) activity by its N-terminal domain. J Biol Chem (2007) 1.35
Loss of CARM1 results in hypomethylation of thymocyte cyclic AMP-regulated phosphoprotein and deregulated early T cell development. J Biol Chem (2004) 1.35
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35
Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol (2004) 1.35
Human protein arginine methyltransferases in vivo--distinct properties of eight canonical members of the PRMT family. J Cell Sci (2009) 1.33
Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat (2005) 1.33
14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res (2002) 1.33
Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res (2007) 1.27
Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. EMBO J (2010) 1.27
Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res (2009) 1.26
Distinct protein arginine methyltransferases promote ATP-dependent chromatin remodeling function at different stages of skeletal muscle differentiation. Mol Cell Biol (2009) 1.26
Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol (2002) 1.24
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia (2008) 1.24
Carm1 regulates Pax7 transcriptional activity through MLL1/2 recruitment during asymmetric satellite stem cell divisions. Cell Stem Cell (2012) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
WWOX protein expression in normal human tissues. J Mol Histol (2006) 1.22
Dynamics of human protein arginine methyltransferase 1(PRMT1) in vivo. J Biol Chem (2005) 1.22
Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci Rep (2013) 1.22
The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6. J Biol Chem (2005) 1.21
Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice. J Biol Chem (2007) 1.21
CARM1 promotes adipocyte differentiation by coactivating PPARgamma. EMBO Rep (2008) 1.21
Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A (2005) 1.19
Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One (2009) 1.18
Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1. J Mol Biol (2008) 1.17
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res (2002) 1.17
Enzymatic activity is required for the in vivo functions of CARM1. J Biol Chem (2009) 1.16
Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene (2004) 1.15
The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain (2013) 1.14
Carcinogenic effects of MGP-7 and B[a]P on the hamster cheek pouch. Toxicol Pathol (2009) 1.14
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol Cell (2013) 1.12
The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog (2012) 1.12
IL7-hCD25 and IL7-Cre BAC transgenic mouse lines: new tools for analysis of IL-7 expressing cells. Genesis (2009) 1.12
Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res (2010) 1.10
PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol (2012) 1.09
Activation of the canonical Wnt/β-catenin pathway in ATF3-induced mammary tumors. PLoS One (2011) 1.08
Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. Cancer Res (2002) 1.08
A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res (2002) 1.08
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene (2003) 1.07
ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol Cell Biol (2002) 1.07
Superovulation strategies for 6 commonly used mouse strains. J Am Assoc Lab Anim Sci (2011) 1.07
From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res (2004) 1.06
Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer (2006) 1.05
Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol (2005) 1.05